Home › Hypopharyngeal Cancer › Michigan › Canton
Hypopharyngeal Cancer clinical trials in Canton, MI
3 studies for Hypopharyngeal Cancer are looking for participants at sites in and around Canton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecruitingPhase 3
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health Medical Center - Canton, Canton
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health Medical Center - Canton, Canton
Hypopharyngeal Cancer trials in other cities
- Atlanta, GA6 studies
- Chicago, IL6 studies
- Kansas City, MO5 studies
- Richmond, VA5 studies
- Stevens Point, WI5 studies
- Wausau, WI5 studies
- Milwaukee, WI5 studies
- Cape Girardeau, MO5 studies
- Peoria, IL5 studies
- Bloomington, IL5 studies
- Joliet, IL5 studies
- Kansas City, KS4 studies
Other studies in Canton
- Lung Cancer9 studies
- Non-Small Cell Lung Cancer8 studies
- Prostate Cancer8 studies
- Acute Myeloid Leukemia7 studies
- Colorectal Cancer6 studies
- Kidney Cancer (Renal Cell Carcinoma)5 studies
- Ovarian Cancer4 studies
- Bladder Cancer4 studies
- Breast Cancer4 studies
- Esophageal Cancer3 studies
- Stomach Cancer3 studies
- Pancreatic Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.